“Bronchopulmonary Dysplasia Pipeline” report has been added to DelveInsight
Bronchopulmonary Dysplasia Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of Bronchopulmonary Dysplasia pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities
Download free sample copy here- https://www.delveinsight.com/sample-request/bronchopulmonary-dysplasia-pipeline-insight
Bronchopulmonary Dysplasia Overview
Bronchopulmonary Dysplasia (BPD) is defined as the need for increased oxygen in infants: 28 d or at discharge (whichever comes first). It applied the clinical criteria from both 28 days of oxygen need and an assessment of respiratory support at 36 weeks’ post menstrual age (PMA).
Bronchopulmonary Dysplasia Pipeline Report
The definition of BPD has evolved throughout the years. The new BPD includes total duration of oxygen supplementation, positive pressure requirements, and gestational age, in addition to oxygen dependency at 36 weeks. The definition allows the severity of the disease to be classified into mild, moderate and severe form, by oxygen dependency and respiratory support at 36 weeks’ PMA.
Bronchopulmonary Dysplasia Pipeline Insights
With the ongoing improvements in neonatal intensive care, both the pathogenesis and histology of BPD has changed, along with reporting in preterm infants. The factors contributing to this disease’s entity can be separated into pre- and post-natal causes such as genetic susceptibility, the immaturity of the surfactant homeostasis, intrauterine and perinatal infections, and lung growth restriction, mechanical ventilation and oxygen therapy induce a pulmonary inflammatory response.
Bronchopulmonary Dysplasia Key Players
Bronchopulmonary Dysplasia Drugs
Bronchopulmonary Dysplasia Report Highlights
Following is the TOC of Bronchopulmonary Dysplasia pipeline report
1. Report Introduction
2. Bronchopulmonary Dysplasia
3. Bronchopulmonary Dysplasia Current Treatment Patterns
4. Bronchopulmonary Dysplasia – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Bronchopulmonary Dysplasia Late Stage Products (Phase-III)
7. Bronchopulmonary Dysplasia Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Bronchopulmonary Dysplasia Discontinued Products
13. Bronchopulmonary Dysplasia Product Profiles
14. Bronchopulmonary Dysplasia Key Companies
15. Bronchopulmonary Dysplasia Key Products
16. Dormant and Discontinued Products
17. Bronchopulmonary Dysplasia Unmet Needs
18. Bronchopulmonary Dysplasia Future Perspectives
19. Bronchopulmonary Dysplasia Analyst Review
20. Appendix
21. Report Methodology
What are the key questions of this report?
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Vinita Rakheja Email: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: www.delveinsight.com/